Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPLSG-ALL-Ph13 trial of chemotherapy plus tyrosine kinase inhibitors in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia
jRCTs041180144Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib and dasatinib in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Three-year event-free survival. Started Oct 2013; status: completed.
02
Drugs
imatinibdasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041180144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180144.